Personalis, Inc. (PSNL)

Market Cap	96.37M
Revenue (ttm)	68.68M
Net Income (ttm)	-113.77M
Shares Out	46.78M
EPS (ttm)	-2.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	405,483
Open	1.96
Previous Close	1.92
Day's Range	1.95 - 2.07
52-Week Range	1.73 - 5.58
Beta	1.41
Analysts	Strong Buy
Price Target	7.00 (+239.81%)
Earnings Date	May 3, 2023

About PSNL

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT D...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 20, 2019
• Employees: 395
• Stock Exchange: NASDAQ
• Ticker Symbol: PSNL

Financial Performance

In 2022, Personalis's revenue was $65.05 million, a decrease of -23.92% compared to the previous year's $85.49 million. Losses were -$113.32 million, 73.7% more than in 2021.

Analyst Forecast

According to 4 analysts, the average rating for PSNL stock is "Strong Buy." The 12-month stock price forecast is $7.0, which is an increase of 239.81% from the latest price.

Price Target

$7.0

(239.81% upside)

Analyst Consensus: Strong Buy